-+ 0.00%
-+ 0.00%
-+ 0.00%

Scancell's Modi-1 immune responses link to longer progression-free survival in Phase 2 kidney cancer trial

PUBT·11/19/2026 07:03:18
Diffusion vocale
Scancell's Modi-1 immune responses link to longer progression-free survival in Phase 2 kidney cancer trial
  • Scancell reported new Phase 2 ModiFY results linking vaccine-specific immune responses to longer progression-free survival in kidney cancer patients receiving Modi-1.
  • Updated Phase 2 SCOPE results showed sustained survival benefits for advanced melanoma patients receiving inzitagene plasmivec with checkpoint inhibitors.
  • The FDA granted inzitagene plasmivec Regenerative Medicine Advanced Therapy designation, providing closer regulatory guidance ahead of its planned December 2026 Phase 3 start.
  • A planned Nasdaq listing in late 2026 or early 2027 would enable financing for the global Phase 3 melanoma trial.
  • More mature SCOPE progression-free survival results and interim overall survival data are expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scancell Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190200PRIMZONEFULLFEED9881077) on November 19, 2026, and is solely responsible for the information contained therein.